Group 1 - The cell immunotherapy sector experienced a significant rally in the afternoon, with Kaineng Health hitting a 20% limit up, and Jimin Health, Zhongyuan Qihe, and Nanjing Xinbai also previously reaching their limit up [1] - Sanyuan Gene saw an increase of over 10%, while Chengda Pharmaceutical and Sunshine Nuohe also followed the upward trend [1] - A recent research paper published in the journal Nature Biotechnology indicates that low-intensity ultrasound treatment can eliminate neurotoxic debris in the brains of mice induced with hemorrhagic stroke [1]

Core Insights - The article discusses the relationship between cerebrospinal fluid (CSF) circulation disorders and various neurological diseases, emphasizing the potential of low-intensity ultrasound treatment to clear harmful debris caused by hemorrhagic stroke, which could lead to improved outcomes without invasive procedures [1][2][5]. Group 1: Research Findings - The study published by Stanford University researchers demonstrates that low-intensity ultrasound can effectively clear harmful debris and inflammation resulting from hemorrhagic stroke [2][5]. - In preclinical models, ultrasound treatment was shown to remove over 50% of red blood cells from the CSF and brain interstitium, facilitating waste clearance through meningeal lymphatics to deep cervical lymph nodes [5][7]. - The ultrasound treatment group exhibited reduced brain inflammation and neuronal damage compared to untreated mice, with improved survival rates and better performance in behavioral tests [5][7]. Group 2: Treatment Implications - The ultrasound treatment method aligns with FDA safety guidelines for ultrasound exposure, and clinical trials are planned to further validate its effectiveness [7]. - If successful in clinical trials, this non-invasive ultrasound therapy could not only benefit hemorrhagic stroke patients but also offer therapeutic advantages for other neurological diseases associated with toxic debris accumulation [7].